Published in Liver Transpl on November 01, 2000
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Transplantation tolerance from a historical perspective. Nat Rev Immunol (2001) 2.04
The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg (2002) 1.81
Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53
Longitudinal tracking of recipient macrophages in a rat chronic cardiac allograft rejection model with noninvasive magnetic resonance imaging using micrometer-sized paramagnetic iron oxide particles. Circulation (2008) 1.38
Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells. Transplantation (2002) 0.81
Cyclic AMP prolongs graft survival by suppressing apoptosis and inflammatory gene expression in acute cardiac allograft rejection. Exp Mol Med (2010) 0.79
The difficulty of eliminating donor leukocyte microchimerism in rat recipients bearing established organ allografts. Transplantation (2006) 0.78
Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation. Liver Transpl (2008) 0.78
The birth of clinical organ transplantation. J Am Coll Surg (2001) 0.76
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 13.88
Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (1974) 13.24
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (1993) 9.81
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology (1985) 7.77
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 6.61
Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 6.49
Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell (1990) 6.33
The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med (2000) 5.74
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med (2000) 5.11
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol (1999) 4.97
Immunology taught by viruses. Science (1996) 4.82
The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med (1992) 4.58
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med (1990) 3.73
Antigen localization and migration in immunity and tolerance. N Engl J Med (1998) 3.71
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
A biological role for the major histocompatibility antigens. Lancet (1975) 3.40
Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 3.17
T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science (1994) 3.00
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med (1999) 2.74
Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev (1997) 2.58
Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med (1998) 2.43
Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1. Immunology (1994) 2.32
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med (1995) 2.07
Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest (1984) 1.91
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (1995) 1.83
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78
The discovery of MHC restriction. Immunol Today (1997) 1.76
The major histocompatibility complex of the rat. Transplantation (1987) 1.76
Pathogenesis of a local graft versus host reaction: immunogenicity of circulating host leukocytes. Science (1968) 1.69
Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med (1998) 1.65
Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. Lancet (1992) 1.61
Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and tumor necrosis factor-alpha. J Immunol (1993) 1.55
Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52
Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A (1996) 1.51
The evolution of self-tolerance: a new cell arises to meet the challenge of self-reactivity. Immunol Today (1998) 1.45
Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol (1997) 1.41
Chimerism and transplantation tolerance: cause and effect. Immunol Today (1996) 1.35
Prolonged survival of actively enhanced rat renal allografts despite accelerated cellular infiltration and rapid induction of both class I and class II MHC antigens. J Exp Med (1987) 1.34
Dendritic cell-lymphoid cell aggregation and major histocompatibility antigen expression during rat cardiac allograft rejection. J Exp Med (1986) 1.32
Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation (1993) 1.24
The linkage between T-cell and dendritic cell development in the mouse thymus. Immunol Rev (1998) 1.24
Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest (1996) 1.24
Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. Transplantation (1998) 1.22
Redistribution of renal allograft-responding leukocytes during rejection. II. Kinetics and specificity. J Exp Med (1982) 1.21
Antiviral immunity. Immunol Today (1997) 1.19
Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation (1999) 1.16
Characterization of the tissue macrophage and the interstitial dendritic cell as distinct leukocytes normally resident in the connective tissue of rat heart. J Exp Med (1990) 1.15
A functional model of hepatocyte transplantation for in vivo immunologic studies. Transplantation (1998) 1.13
Cardiac transplantation in the rat. I. The effect of histocompatibility differences on graft arteriosclerosis. Transplantation (1989) 1.12
Lymphocytic subsets and histopathologic changes associated with the development of heart transplant arteriosclerosis. J Heart Lung Transplant (1992) 1.09
Retracted Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation (1999) 1.05
Donor hematopoietic progenitor cells in nonmyeloablated rat recipients of allogeneic bone marrow and liver grafts. Transplantation (1999) 1.04
Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection. Nat Med (1998) 1.01
Characterization and expression of the antigen present on resident rat macrophages recognized by monoclonal antibody ED2. Immunobiology (1990) 1.00
Antigen-independent determinants of cadaveric kidney transplant failure. JAMA (1996) 0.99
Experimental graft arteriosclerosis. II. Immunocytochemical analysis of lesion development. Transplantation (1993) 0.99
In vivo immunogenicity of purified allogeneic hepatocytes in a murine hepatocyte transplant model. Transplantation (1998) 0.95
An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation (1996) 0.94
The RGD-containing domain of exogenous HIV-1 Tat inhibits the engulfment of apoptotic bodies by dendritic cells. AIDS (1997) 0.94
Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest (1994) 0.93
Macrophage subpopulations in normal and transplanted heart and kidney tissues in the rat. Transplantation (1992) 0.92
A monoclonal antibody (L21-6) recognizing an invariant chain expressed on the cell surface in rats with the exception of the BN (RT1n): a study of tissue and strain distributions. Transplant Proc (1995) 0.91
Tolerance to rat liver allografts. III. Donor cell migration and tolerance-associated cytokine production in peripheral lymphoid tissues. J Immunol (1996) 0.91
Chronic rejection of rat renal allografts. II. The impact of prolonged ischemia time on transplant histology. Transplantation (1992) 0.88
Stable lung allograft outcome correlates with the presence of intragraft donor-derived leukocytes. Transplantation (1998) 0.85
Infusion of donor leukocytes to induce tolerance in organ allograft recipients. J Leukoc Biol (1999) 0.85
Apoptosis of T lymphocytes in liver and/or small bowel allografts during tolerance induction. Transplantation (1998) 0.85
Synthetic MHC class I peptide prolongs cardiac survival and attenuates transplant arteriosclerosis in the Lewis-->Fischer 344 model of chronic allograft rejection. Transplantation (1997) 0.81
Costimulation pathways in host immune responses to allogeneic hepatocytes. Transplantation (1998) 0.79
The requirement for allogeneic chimerism for second transfer of tolerance from mixed allogeneic chimeras (A+B-->A) to secondary recipients. Transplantation (1992) 0.77
Evolution of liver transplantation. Hepatology (1982) 19.54
CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol (1988) 15.40
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Bone marrow as a potential source of hepatic oval cells. Science (1999) 8.52
Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11
Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature (1997) 7.49
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging (1999) 4.94
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Liver transplantation (1). N Engl J Med (1989) 4.53
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med (1997) 4.27
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08
Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) Study. Control Clin Trials (1987) 4.05
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Delineating the genetic basis of systemic lupus erythematosus. Immunity (2001) 4.02
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Abnormal glucose metabolism and pancreatic cancer mortality. JAMA (2000) 4.01
Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA (2001) 3.90
Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs. N Engl J Med (1998) 3.89
The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science (2000) 3.72
Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease. J Vasc Surg (2000) 3.33
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Cardiovascular risk factors in young adults. The CARDIA baseline monograph. Control Clin Trials (1991) 3.30
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26